104PEfficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: Results of the Italian compassionate use program
Metro, G., Passaro, A., Lo Russo, G., Gregorc, V., Giusti, R., Capelletto, E., Martelli, O., Cecere, F.L., Bonanno, L., Chiari, R.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx091.024
Date:
April, 2017
File:
PDF, 41 KB
english, 2017